• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

Despite guideline recommendations and available evidence, implementation of treatment in
heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

The overall lifetime risk of heart failure (HF) is similar between men and women, however,
there are marked sex differences in the landscape of this condition that are both important …

Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …

Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and
kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate
(eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction …